AUTOLUS THERAPEUTICS PLC (AUTL) Fundamental Analysis & Valuation
NASDAQ:AUTL • US05280R1005
Current stock price
1.43 USD
-0.02 (-1.38%)
At close:
1.46 USD
+0.03 (+2.1%)
After Hours:
This AUTL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AUTL Profitability Analysis
1.1 Basic Checks
- In the past year AUTL has reported negative net income.
- AUTL had a negative operating cash flow in the past year.
- In the past 5 years AUTL always reported negative net income.
- In the past 5 years AUTL always reported negative operating cash flow.
1.2 Ratios
- AUTL has a better Return On Assets (-33.96%) than 62.55% of its industry peers.
- The Return On Equity of AUTL (-84.69%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.96% | ||
| ROE | -84.69% | ||
| ROIC | N/A |
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for AUTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. AUTL Health Analysis
2.1 Basic Checks
- AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AUTL has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -2.66, we must say that AUTL is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of AUTL (-2.66) is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.95 indicates that AUTL is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.95, AUTL is doing worse than 74.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.66 |
ROIC/WACCN/A
WACC7.43%
2.3 Liquidity
- A Current Ratio of 6.19 indicates that AUTL has no problem at all paying its short term obligations.
- AUTL's Current ratio of 6.19 is fine compared to the rest of the industry. AUTL outperforms 63.51% of its industry peers.
- AUTL has a Quick Ratio of 5.86. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of AUTL (5.86) is better than 63.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.86 |
3. AUTL Growth Analysis
3.1 Past
- AUTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.15%, which is quite impressive.
- AUTL shows a strong growth in Revenue. In the last year, the Revenue has grown by 496.00%.
- AUTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.31% yearly.
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 15.81% on average over the next years. This is quite good.
- Based on estimates for the next years, AUTL will show a very strong growth in Revenue. The Revenue will grow by 113.07% on average per year.
EPS Next Y-16.3%
EPS Next 2Y0.07%
EPS Next 3Y7.49%
EPS Next 5Y15.81%
Revenue Next Year503.16%
Revenue Next 2Y229.29%
Revenue Next 3Y164.61%
Revenue Next 5Y113.07%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. AUTL Valuation Analysis
4.1 Price/Earnings Ratio
- AUTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.07%
EPS Next 3Y7.49%
5. AUTL Dividend Analysis
5.1 Amount
- AUTL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AUTL Fundamentals: All Metrics, Ratios and Statistics
1.43
-0.02 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2026-03-18/amc
Earnings (Next)05-06 2026-05-06
Inst Owners69.43%
Inst Owner Change-1.22%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap380.58M
Revenue(TTM)51.13M
Net Income(TTM)-224.80M
Analysts85.56
Price Target8.89 (521.68%)
Short Float %6.62%
Short Ratio7.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.59%
Min EPS beat(2)-30.31%
Max EPS beat(2)25.13%
EPS beat(4)2
Avg EPS beat(4)11.3%
Min EPS beat(4)-30.31%
Max EPS beat(4)52.34%
EPS beat(8)2
Avg EPS beat(8)-51.27%
EPS beat(12)4
Avg EPS beat(12)-32.86%
EPS beat(16)6
Avg EPS beat(16)-24.54%
Revenue beat(2)1
Avg Revenue beat(2)28.11%
Min Revenue beat(2)-2.73%
Max Revenue beat(2)58.95%
Revenue beat(4)2
Avg Revenue beat(4)70.92%
Min Revenue beat(4)-99.05%
Max Revenue beat(4)326.5%
Revenue beat(8)2
Avg Revenue beat(8)-9.59%
Revenue beat(12)4
Avg Revenue beat(12)7.38%
Revenue beat(16)5
Avg Revenue beat(16)97.39%
PT rev (1m)-2.81%
PT rev (3m)-6.26%
EPS NQ rev (1m)-2.97%
EPS NQ rev (3m)-9.63%
EPS NY rev (1m)-0.65%
EPS NY rev (3m)-2.74%
Revenue NQ rev (1m)-2.24%
Revenue NQ rev (3m)1.06%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)1.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.43 | ||
| P/tB | 1.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.19
BVpS1
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.96% | ||
| ROE | -84.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 560.18% | ||
| Cap/Sales | 101.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.86 | ||
| Altman-Z | -2.66 |
F-Score2
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)254.9%
Cap/Depr(5y)225.76%
Cap/Sales(3y)387.17%
Cap/Sales(5y)479.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
EPS Next Y-16.3%
EPS Next 2Y0.07%
EPS Next 3Y7.49%
EPS Next 5Y15.81%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A
Revenue Next Year503.16%
Revenue Next 2Y229.29%
Revenue Next 3Y164.61%
Revenue Next 5Y113.07%
EBIT growth 1Y-37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.86%
EBIT Next 3Y9.49%
EBIT Next 5Y23.74%
FCF growth 1Y-110.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.84%
OCF growth 3YN/A
OCF growth 5YN/A
AUTOLUS THERAPEUTICS PLC / AUTL Fundamental Analysis FAQ
What is the fundamental rating for AUTL stock?
ChartMill assigns a fundamental rating of 3 / 10 to AUTL.
What is the valuation status of AUTOLUS THERAPEUTICS PLC (AUTL) stock?
ChartMill assigns a valuation rating of 0 / 10 to AUTOLUS THERAPEUTICS PLC (AUTL). This can be considered as Overvalued.
How profitable is AUTOLUS THERAPEUTICS PLC (AUTL) stock?
AUTOLUS THERAPEUTICS PLC (AUTL) has a profitability rating of 1 / 10.
Can you provide the financial health for AUTL stock?
The financial health rating of AUTOLUS THERAPEUTICS PLC (AUTL) is 4 / 10.
What is the earnings growth outlook for AUTOLUS THERAPEUTICS PLC?
The Earnings per Share (EPS) of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to decline by -16.3% in the next year.